Annovis Bio (FRA:07X) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:07X Annovis Bio Inc FRA:07X
38 GF Score
Price €1.70
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


FRA:07X vs HYFT, EXOZ, ACRV: Short Interest Comparison

For the Biotechnology subindustry, Annovis Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Short Interest falls into.


FRA:07X
38GF Score
Annovis Bio Inc FRA:07X
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
38GF Score

Get the complete analysis for FRA:07X

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.70
Price